Search

Your search keyword '"Yee, Donald"' showing total 19 results
Start Over Author "Yee, Donald" Journal blood
19 results on '"Yee, Donald"'

3. Data Coming out of the Human Inhibitor PUP Study (HIPS) Reveal 4 Subgroups of Patients with Distinct Antibody Signatures

Author

Gangadharan, Bagirath, primary, Reipert, Birgit M, additional, Berg, Verena, additional, Scheiflinger, Friedrich, additional, Blatny, Jan, additional, Fijnvandraat, K, additional, Gruppo, Ralph A., additional, Klintman, Jenny, additional, Male, Christoph, additional, McGuinn, Catherine E., additional, Meeks, Shannon L., additional, Radulescu, Vlad Calin, additional, Ragni, Margaret V., additional, Recht, Michael, additional, Santagostino, Elena, additional, Shapiro, Amy, additional, Staber, Janice, additional, Yaish, Hassan M., additional, Yee, Donald L, additional, and Brown, Deborah, additional

Published
2018
Full Text
View/download PDF

4. Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia Α- New Insights from the Hemophilia Inhibitor PUP Study (HIPS)

Author

Gangadharan, Bagirath, primary, Reipert, Birgit, additional, Scheiflinger, Fritz, additional, Bowen, Joel, additional, Donnachie, Elizabeth, additional, Fijn van Draat, Karin, additional, Gruppo, Ralph A., additional, Klintman, Jenny, additional, Male, Christoph, additional, McGuinn, Catherine E., additional, Meeks, Shannon L., additional, Recht, Michael, additional, Ragni, Margaret V., additional, Yaish, Hassan M., additional, Shapiro, Amy D., additional, Yee, Donald L, additional, Radulescu, Vlad Calin, additional, Santagostino, Elena, additional, and Brown, Deborah, additional

Published
2017
Full Text
View/download PDF

5. Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)

Author

Morschhauser, Franck, Patel, Krish, Bobillo, Sabela, Cordoba, Raul, Eyre, Toby A., Bishton, Mark, Houot, Roch, Zhang, Hui-Lai, Zou, Liqun, Osborne, Wendy, Gálvez-Carvajal, Laura, Thieblemont, Catherine, Yee, Donald, Knapp, Andrea, Purev, Enkhtsetseg, Li, Haocheng, Chen, Vivian, Banta, Karl L., Sit, Jason, and Bachy, Emmanuel

Abstract

Background:First-line FL treatments typically include an anti-CD20 monoclonal antibody with alkylator-based chemotherapy. Despite encouraging efficacy, most patients (pts) eventually relapse; novel therapies that improve outcomes and prolong remission in 1L FL are needed. Also, chemotherapy-containing regimens may have substantial toxicities, emphasizing the need for new therapies with improved safety. Mosunetuzumab (M), a CD20xCD3 bispecific antibody that redirects T cells to eliminate malignant B cells, has shown manageable safety with high complete remission rates in pts with relapsed/refractory (R/R) FL after ≥2 prior lines of therapy (Budde et al. Lancet Oncol 2022). Lenalidomide (Len), a potent immunomodulatory agent, may have synergistic effects with M. Initial results from the CO41942 Phase Ib/II trial (NCT04246086) showed that M (intravenous) combined with Len had a manageable safety profile and encouraging chemotherapy-free anti-lymphoma activity in pts with R/R FL who had ≥1 prior line of therapy (Morschhauser et al. ASH 2021). We present preliminary safety, efficacy, and biomarker data from this ongoing trial of M (subcutaneous [SC]) combined with oral Len in pts with 1L FL who require systemic therapy.

Published
2023
Full Text
View/download PDF

10. Validation Study Of The Composite Score To Identify Von Willebrand Disease in Children

Author

Malec, Lynn M., primary, Moore, Charity G., additional, Bennett, Carolyn M., additional, Yee, Donald L, additional, Kerlin, Bryce A., additional, Witmer, Char, additional, Gunawardena, Sriya, additional, Kulkarni, Roshni, additional, Gupta, Sweta, additional, Kouides, Peter A., additional, Brown, Deborah, additional, Bujnicki, Heather L., additional, and Ragni, Margaret V., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results